Clinical Trial: GDF 15 in Sickle Cell Disease and Hereditary Spherocytosis

Study Status: Recruiting
Recruit Status: Unknown status
Study Type: Observational

Official Title: The Impact of Growth Differentiating Factor (GDF) 15 in Sickle Cell Disease and Hereditary Spherocytosis

Brief Summary: Patients with thalassemia intermedia, congenital dyserythropoietic anemia type I , and sideroblastic anemia were found to express very high levels of serum GDF15, and this contributed to the inappropriate suppression of hepcidin with subsequent secondary iron overload.The aim of our present study is to asses the levels of GDF15 and hepcidin in patients with Sickle cell disease and hereditary spherocytosis

Detailed Summary:

The identification of the ferroportin/hepcidin axis has allowed the effect of erythroid activity on iron balance to be studied and has created the basis for better defining the erythroid regulators.

In iron-loading anemias, ineffective erythropoiesis suppresses hepcidin production, which result in dysregulating iron homeostasis. Miller and co-workers showed that release of cytokines like growth differentiation factor 15 (GDF15) during the process of ineffective erythropoiesis inhibits hepcidin production, thus defining a molecular link between ineffective erythropoiesis, suppression of hepcidin production and parenchymal iron loading.

Sponsor: Wolfson Medical Center

Current Primary Outcome: GDF 15 [ Time Frame: year ]

Original Primary Outcome: Same as current

Current Secondary Outcome: Hepcidine [ Time Frame: year ]

Original Secondary Outcome: Same as current

Information By: Wolfson Medical Center

Dates:
Date Received: September 12, 2010
Date Started: September 2010
Date Completion: September 2011
Last Updated: September 12, 2010
Last Verified: September 2010